HYXIM (Cefixime) is a broad spectrum cephalosporin antibiotic of third generation for oral administration. It is a bactericidal antibiotic and is stable to hydrolysis by many beta-lactamases. HYXIM kills bacteria by interfering the synthesis of the bacterial cell wall. HYXIM is highly active against Neisseria Gonorrhoeae, Haemophilus Influenzae, Moraxella catarrhalis including beta-lactamase producers, most of the Enterobacteriaceae, Beta-Haemolytic Streptococci (Group A & B) and Streptococcus Pneumoniae, HYXIM is more active than other oral cephalosporins against Escherichia coli, Klebsiella spp, Proteus mirabilis and Serratia marcescens. HYXIM is also active against Streptococcus pyogenes. 40-50% of an oral dose is absorbed from gastro-intestinal tract, whether taken with meals or not. The plasma half-life is usually about 3 to 4 hours and may be prolonged when there is renal impairment. About 65% is bound to plasma protein. HYXIM is mainly excreted unchanged in bile and urine.
HYXIM-200 Capsule: Each capsule contains Cefixime Trihydrate BP equivalent to anhydrous Cefixime 200 mg.
HYXIM Powder for Suspension:
After preparation each 5 ml contains Cefixime Trihydrate BP equivalent to anhydrous Cefixime 100 mg.
It is indicated for the treatment of the following acute infection, when caused by susceptible
- Urinary tract infections : Cystitis, Cystourethritis, Pyelonephritis, Gonococcal Urethritis.
- Upper respiratory tract infections : Otitis media, and other URTI
where the causative organism is known or suspected to be resistant
to other commonly used antibiotics.
- Lower respiratory tract infections : Bronchitis, etc.
- Typhoid fever
Dosage and administration:
HYXIM Capsule :
Adult : 1 or 2 capsules (200-400 mg) as a single dose or in two divided
doses daily for 7-14 days, according to the severity of the infection.
Children above 6 months: 8 mg per kg body weight as a single dose or in two divided doses for 7-14 days according to the severity of the infection or as following:
6 months-1 year : 3.75 ml or 75 mg
1-4 years : 5 ml or 100 mg
5-10 years : 10 ml or 200 mg
11-12 years : 15 ml or 300 mg
Above 12 years : Adult dose may be administered
Children under 6 months: Not recommended.
HYXIM is generally well tolerated. The majority of adverse reactions observed in clinical trials was mild and self-limiting in nature. Gastro-intestinal disturbances : Diarrhoea (if severe diarrhoea occurs, HYXIM should be discontinued), changes in the color of stool, Nausea, Abdominal pain, Dyspepsia, Vomiting, Flatulence have been reported. Central nervous system disturbances : Headache, Dizziness, etc. Others : Hypersensitivity reactions which usually subsided upon discontinuation of therapy; infrequent and reversible haematological changes; elevation of serum amylase, etc.
Patients with known Hypersensitivity to Cephalosporin Antibiotics, children under 6 months.
HYXIM should be prescribed with caution in individuals with a history of Gastro-Intestinal Disease, Particularly Colitis. Dosage adjustment is only necessary in severe renal failure (creatinine clearance <20 ml/ min).
Use in pregnancy and lactation:
No data are available, so it is probably best to avoid using the drug during pregnancy and by the nursing mothers.
No data are available
Store at normal temperature and away from sun light.
HYXIM-200 Capsule: Box containing 1x6's capsules in alu-alu blister pack.
HYXIM Powder for Suspension: Bottle containing dry powder for Preparation of 50 ml suspension.